Bioiberica increases product sales on international markets
Bioiberica has followed a vertical integration strategy in the last three years towards the development and sale of finished products. All products undergo scientific and clinical development and have their own marketing strategy to support sales in each country.
Results have been consolidated over the years and the company's products in the Joint Care line are now being marketed in Italy, Germany, Belgium, the Netherlands, Greece, Turkey and Slovenia. Further launches in Europe and Asia are planned in 2010. Bioiberica has also reached an important agreement with Merck KGaA for product distribution in several countries.
One of the company's aims is to expand its Joint Care portfolio to other therapeutic areas such as immunology: In 2009 Bioiberica launched Inmunactive in Spain, its first product designed to preserve and improve compromised immune systems. In 2010 the product will be launched on international markets.
Related News
As Bioiberica celebrates its 50th anniversary, Luis Solera, CEO reflects on the company’s evolution—from a pioneer in heparin production to a global leader in the biotech industry.
